|
|
|
|
|
|
|
|
2004年 |
千葉大学医学部 卒業 |
2004年 |
国立精神・神経センター国府台病院 初期研修医
|
2006年 |
千葉大学医学部附属病院 泌尿器科 後期研修医 |
2007年 |
千葉県がんセンター 泌尿器科 医員 |
2009年 |
千葉大学医学部附属病院 泌尿器科 医員 |
2012年 |
千葉県がんセンター 泌尿器科 医員 |
2013年 |
千葉大学大学院医学薬学府博士課程(先進医療科学専攻泌尿器科学)修了 学位(医学博士号)取得
|
2013年 |
BC Cancer Agency Genome Sciences Centre (Canada) 博士研究員 |
2016年 |
千葉大学医学部附属病院 泌尿器科 助教 |
2020年 |
千葉大学医学部附属病院 泌尿器科 講師 |
現在に至る |
|
|
|
|
・日本泌尿器科学会 (専門医) ・日本泌尿器内視鏡学会(泌尿器科腹腔鏡技術認定医) ・日本内視鏡外科学会(泌尿器科腹腔鏡技術認定医) ・日本内分泌学会内分泌代謝科(泌尿器科)専門医 ・日本内分泌外科学会 ・日本癌治療学会 ・日本泌尿器分子・細胞研究会 ・日本尿路結石症学会 ・日本泌尿器腫瘍学会 ・日本アンドドロジー学会(評議員) ・日本人類遺伝学会 ・日本生殖医学会 ・Society for Basic Urologic Research(SBUR) ・米国泌尿器科学会(AUA) ・International Journal of Urology編集幹事
|
|
|
|
・泌尿器科一般 ・泌尿器腫瘍学
|
|
|
|
・2013年 千葉大学大学院医学研究院泌尿器科同門会学術奨励島崎賞 ・2017年 International Uro-Oncological Symposium in Taiwan Best E-poster Award
|
|
|
|
・科学研究費助成金 若手研究スタート支援 平成28年 - 平成29年度 ・科学研究費助成金 若手(B) 平成29年度 - 平成31年度 ・科学研究費助成金 基盤(C) 令和2年度 - 令和4年度
|
|
|
|
・前立腺癌における新規薬剤の解明
|
|
|
|
Yamada Y, Sakamoto S, Rii J, Yamamoto S, Kamada S, Imamura Y, Nakamura K, Komiya A, Nakatsu H, Ichikawa T. Prognostic value of an inflammatory index for patients with metastatic castration-resistant prostate cancer. Prostate. 2020 Mar 5.
Nakamura K, Imamura Y, Yamamoto S, Sazuka T, Sakamoto S, Ichikawa T. Soft coagulation in robot-assisted partial nephrectomy without renorrhaphy: Comparison with standard suture. Int J Urol. 2020 Apr;27(4):352-354.
Yamada Y, Sakamoto S, Rii J, Yamamoto S, Kamada S, Imamura Y, Nakamura K, Komiya A, Nakatsu H, Ichikawa T. How many bone metastases may be defined as high-volume metastatic prostate cancer in Asians: A retrospective multicenter cohort study. Prostate. 2020 Apr;80(5):432-440.
Maimaiti M, Sakamoto S, Yamada Y, Sugiura M, Rii J, Takeuchi N, Imamura Y, Furihata T, Ando K, Higuchi K, Xu M, Sazuka T, Nakamura K, Kaneda A, Kanai Y, Kyprianou N, Ikehara Y, Anzai N, Ichikawa T. Expression of L-type amino acid transporter 1 as a molecular target for prognostic and therapeutic indicators in bladder carcinoma. Sci Rep. 2020 Jan 28;10(1):1292.
Ando K, Sakamoto S, Takeshita N, Fujimoto A, Maimaiti M, Saito S, Sanjyon P, Imamura Y, Sato N, Komiya A, Akakura K, Ichikawa T. Higher serum testosterone levels predict poor prognosis in castration-resistant prostate cancer patients treated with docetaxel. Prostate. 2020 Feb;80(3):247-255.
Higuchi K, Sakamoto S, Ando K, Maimaiti M, Takeshita N, Okunushi K, Reien Y, Imamura Y, Sazuka T, Nakamura K, Matsushima J, Furihata T, Ikehara Y, Ichikawa T, Anzai N. Characterization of the expression of LAT1 as a prognostic indicator and a therapeutic target in renal cell carcinoma. Sci Rep. 2019 Nov 20;9(1):16776.
Sazuka T, Sakamoto S, Nakamura K, Imamura Y, Yamamoto S, Komiya A, Ichikawa T. Impact of post-void residual urine volume on intravesical recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma. Int J Urol. 2019 Dec;26(12):1106-1112.
Yamamoto S, Sakamoto S, Imamura Y, Sazuka T, Nakamura K, Inoue T, Chiba K, Miyazaki K, Inoue A, Nagata M, Ichikawa T. Intravesical irrigation might prevent bladder recurrence in patients undergoing radical nephroureterectomy for upper urinary tract urothelial carcinoma. Int J Urol. 2019 Aug;26(8):791-796.
Sugiura M, Imamura Y, Kawamura K, Yamamoto S, Sazuka T, Nakamura K, Sakamoto S, Nagano H, Koide H, Tanaka T, Imamoto T, Komiya A, Ichikawa T. Contralateral adrenal width predicts the duration of prolonged post-surgical steroid replacement for subclinical Cushing syndrome. Int J Urol. 2018 Jun;25(6):583-588.
Takeuchi N, Sakamoto S, Nishiyama A, Horikoshi T, Yamada Y, Iizuka J, Maimaiti M, Imamura Y, Kawamura K, Imamoto T, Komiya A, Ikehara Y, Akakura K, Ichikawa T. Biparametric Prostate Imaging Reporting and Data System version2 and International Society of Urological Pathology Grade Predict Biochemical Recurrence after Radical Prostatectomy. Clin Genitourin Cancer. 2018 Feb 24 (4): e817-e829.
Takei A, Sakamoto S, Wakai K, Tamura T, Imamura Y, Xu M, Maimaiti M, Kawamura K, Imamoto T, Komiya A, Akakura K, Ichikawa T. Duration of androgen deprivation therapy and nadir of testosterone at 20 ng/dL predict testosterone recovery to supracastrate level in prostate cancer patients who received external beam radiotherapy. Int J Urol. 2018 Apr 25 (4):352-358.
Nakamura K, Goto Y, Sazuka T, Imamura Y, Komiya A, Ichikawa T. [KOUJIN POWDER (RED GINSENG POWDER) WITH NINJIN-YOUEITO FOR FATIGUE DUE TO TARGETED THERAPY FOR ADVANCED RENAL CELL CARCINOMA: A RETROSPECTIVE COHORT STUDY]. Nihon Hinyokika Gakkai Zasshi. 2017;108(4):194-199.
Banuelos CA, Tavakoli I, Tien AH, Caley DP, Mawji NR, Li Z, Wang J, Yang YC, Imamura Y, Yan L, Wen JG, Andersen RJ, Sadar MD. J Biol Chem. 2016 Aug 30. Sintokamide A is a Novel Antagonist of Androgen Receptor that Uniquely Binds Activation Function-1 in its Amino-Terminal Domain.
Imamura Y, Sadar MD. Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic. Int J Urol. 2016 Aug;23(8):654-65.
Imamura Y, Tien AH, Pan J, Leung JK, Banuelos CA, Jian K, Wang J, Mawji NR, Fernandez JG, Lin KS, Andersen RJ, Sadar MD. JCI Insight. 2016 Jul 21. An imaging agent to detect androgen receptor and its active splice variants in prostate cancer.
Kato M, Banuelos CA, Imamura Y, Leung JK, Caley DP, Wang J, Mawji NR, Sadar MD. Clin Cancer Res. 2015 Dec 28. Cotargeting Androgen Receptor Splice Variants and mTOR Signaling Pathway for the Treatment of Castration-Resistant Prostate Cancer.
Namekawa T, Fukasawa S, Komaru A, Kobayashi M, Imamura Y, Ohzeki T, Takagi K, Sato Y, Akakura K, Ichikawa T, Ueda T. Int J Clin Oncol. 2015 Dec;20(6):1185-91.Prospective evaluation of the safety of transrectal ultrasound-guided transperineal prostate biopsy based on adverse events.
Utsumi T, Suyama T, Imamura Y, Fuse M, Sakamoto S, Nihei N, Ueda T, Suzuki H, Seki N, Ichikawa T. J Urol. 2014 Aug;192(2):567-74. The association of CXCR3 and renal cell carcinoma metastasis.
Imamura Y, Kawamura K, Sazuka T, Sakamoto S, Imamoto T, Nihei N, Suzuki H, Okano T, Nozumi K, Ichikawa T. Int J Urol. 2013 Jun;20(6):616-21.Development of a nomogram for predicting the stone-free rate after transurethral ureterolithotripsy using semi-rigid ureteroscope.
Imamura Y, Sakamoto S, Endo T, Utsumi T, Fuse M, Suyama T, Kawamura K, Imamoto T, Yano K, Uzawa K, Nihei N, Suzuki H, Mizokami A, Ueda T, Seki N, Tanzawa H, Ichikawa T. PLoS One. 2012;7(8):e42456.FOXA1 promotes tumor progression in prostate cancer via the insulin-like growth factor binding protein 3 pathway.
Ueda T, Imamura Y, Komaru A, Fukasawa S, Sazuka T, Suyama T, Naya Y, Nihei N, Ichikawa T, Maruoka M. Int J Urol. 2010 Sep;17(9):811-5.Treatment outcomes of sorafenib for first line or cytokinerefractory advanced renal cell carcinoma in Japanese patients.
Suyama T, Ueda T, Fukasawa S, Imamura Y, Nakamura K, Miyasaka K, Sazuka T, Egoshi K, Nihei N, Hamano M, Ichikawa T, Maruoka M. Jpn J Clin Oncol. 2009 Apr;39(4):244-50.Combination of gemcitabine and paclitaxel as second-line chemotherapy for advanced urothelial carcinoma.
|
|
|
|
|
|
|
|
|